Introduction: Ischaemia-reperfusion injury following acute myocardial infarctions (AMI) is an unavoidable consequence of the primary percutaneous coronary intervention (pPCI) procedure. A pivotal mechanism in ischaemia-reperfusion injury is the production of reactive oxygen species following reperfusion. The endogenous hormone, melatonin, works as an antioxidant and could potentially minimise the ischaemia-reperfusion injury. Given intracoronarily, it enables melatonin to work directly at the site of reperfusion. We wish to test if melatonin, as an antioxidant, can minimise the reperfusion injury following pPCI in patients with AMI.
Material And Methods: The IMPACT trial is a multicentre, randomised, double-blinded, placebo-controlled study. We wish to include 2 × 20 patients with ST-elevation myocardial infarctions undergoing pPCI within six hours from symptom onset. The primary end-point is the Myocardial Salvage Index assessed by cardiovascular magnetic resonance imaging on day 4 (± 1) after pPCI. The secondary end-points are high-sensitivity troponin, creatinekinase myocardial band and clinical events.
Conclusion: The aim of the IMPACT trial is to evaluate the effect of melatonin on reperfusion injuries following pPCI. Owing to its relatively non-toxic profile, melatonin is an easily implementable drug in the clinical setting, and melatonin has the potential to reduce morbidity in patients with AMI.
Funding: This study received no financial support from the industry.
Trial Registration: www.clinicaltrials.gov, clinical trials identifier: NCT01172171.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Net Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Importance: The net clinical effect of early vs later direct oral anticoagulant (DOAC) initiation after atrial fibrillation-associated ischemic stroke is unclear.
Objective: To investigate whether early DOAC treatment is associated with a net clinical benefit (NCB).
Design, Setting, And Participants: This was a post hoc analysis of the Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation (ELAN) open-label randomized clinical trial conducted across 103 sites in 15 countries in Europe, the Middle East, and Asia between November 6, 2017, and September 12, 2022, with a 90-day follow-up.
Understanding of Clinical Trials Among Patients With Cancer and Their Relatives.
JAMA Netw Open
January 2025
Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
Importance: Clinical trials are vital for advancing cancer treatments and improving patient outcomes. Understanding the factors that influence participants' decision-making is critical for enhancing trial recruitment.
Objective: To evaluate the attitudes of patients with cancer and their relatives toward clinical trial participation, identifying key barriers and motivators that affect their willingness to engage in such trials.
Effect of Education on Nutritional Knowledge of Cancer Prevention based on Health Belief Model: A Systematic Review and Meta-Analysis.
Asian Pac J Cancer Prev
January 2025
Counseling and Reproductive Health Research Center, Department of Midwifery, School of Nursing and Midwifery, Golestan University of Medical Sciences, Gorgan, Iran.
Objective: This systematic review was conducted to examine the impact of education on nutritional knowledge for cancer prevention using the Health Belief Model.
Methods: Comprehensive searches were performed in international electronic databases, including Scopus, PubMed, and Web of Science, from their inception until June 16, 2024. Keywords derived from Medical Subject Headings such as "Nutrition Knowledge," "Education," "Health Belief Model," and "Cancer" were utilized.
Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.
Paediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFA Systematic Review and Meta-Analysis Assessing the Impact of Improved Cookstove Technology Trials (ICTs) on Household Air Pollution and Human Health in Sub-Saharan Africa.
Curr Environ Health Rep
January 2025
Center for Public Health and Environmental Assessment, United States Environmental Protection Agency, 104 Mason Farm Rd., Chapel Hill, NC, 27514, USA.
Purpose Of Review: A major contributor to household air pollution (HAP) in sub-Saharan Africa (SSA) is unclean cooking fuel. Improved cookstove technology (ICT) interventions have been promoted as a solution, but their impacts on health are unclear. Our aim is to conduct a systematic review to explore the impacts of ICT interventions on health outcomes in SSA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!